• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NeuroMetrix back in NASDAQ’s good graces, hits diabetes market with new test

NeuroMetrix back in NASDAQ’s good graces, hits diabetes market with new test

September 20, 2011 By MassDevice staff

NeuroMetrix

A 1-for-6 reverse stock split worked out for NeuroMetrix Inc. (NSDQ:NUROD), which said today that it’s back in the good graces of the NASDAQ exchange, and announced a new product launch for the diabetes market.

The Waltham, Mass.-based company, a former high flier on Wall Street, has fallen back to earth after hitting a high-water mark of $39.35 per share in August 2006.

When share prices fell below $1 apiece for 30 consecutive days last year, the stock exchange warned of a potential delisting if share prices stayed below the $1 threshold.

That prompted NeuroMetrix, which makes equipment to test nerve conduction, to ask its shareholders to approve the reverse split back in April. Earlier this month the company pulled the trigger on the split and its share price responded. NURO shares have bounced between $1.71 and $2.30 since the Sept. 2 split and were trading at $1.72 as of about 10:50 today, down 2.8 percent on the day.

Sign up to get our free newsletters delivered straight to your inbox

NeuroMetrix also said it shipped the first of its new product line aimed at the diabetes market. Its NC-stat DPNCheck point-of-care test is designed to evaluate systemic neuropathies such as diabetic peripheral neuropathy.

“NeuroMetrix believes that the NC-stat DPNCheck test may address the unmet medical need for better, cost-effective approaches to detecting and monitoring DPN,” according to a press release. “Commercial shipment represents the culmination, on schedule, of a year-long product development effort to modify the company’s NC-stat technology to the focused evaluation of the sural nerve. In tandem, the development effort resulted in substantial cost reductions that enable an innovative approach to commercial deployment of this important advance in diabetes care.”

NeuroMetrix is also co-developing an over-the-counter version of the NC-Stat test for DPN, along with Japan’s Nipro Corp. (TYO:8086).

Early this year the company said it planned to stop supporting its workhorse NC-stat device for neurodiagnostics and pursue its use for diabetic indications instead. The general purpose NC-stat suffered a setback it never got over after the Centers for Medicare and Medicaid Services cut reimbursement rates for procedures using the device.

Filed Under: News Well, Wall Street Beat Tagged With: Neurometrix, Nipro

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy